Abstract
Background Potentially inappropriate medications for older adults are those that offer more risks than benefits for this population. Such medications found in older adults’ prescriptions across the world are associated with higher rates of comorbidities and hospitalizations, along with high expenditure on healthcare resources. Objectives To estimate the frequency of older adults using potentially inappropriate medications according to four different criteria, to identify factors associated with the use of such medicines and differences between the tools. Setting A primary healthcare unit linked to a university hospital in Porto Alegre, Brazil. Method This was a cross-sectional study conducted via data collection from the electronic medical records of 390 older adults. The information collected comprised sex, age, chronic diseases diagnosed and medications used. The dependent variable of the study was the use of at least one potentially inappropriate medication, according to the following criteria: Beers, Screening Tool of Older Persons’ Prescriptions (STOPP), Brazilian consensus and Anticholinergic Risk Scale (ARS). Main outcome measurement Prevalence of inappropriate medication, differences between the tools and associated factors. Results: The use of at least one potentially inappropriate medication was found in 55.1% of the sample according to the Beers criterion, 51.3% according to the Brazilian consensus, 42.6% according to STOPP and 23.6% according to ARS. It was also seen that 14.9% of the studied population was exposed to a very strong anticholinergic risk. Depending on which tools were used, the agreement observed between the criteria was considered high, moderate, or low. Regarding the four criteria, the use of potentially inappropriate medication is associated with polypharmacy, the diagnosis of three or more chronic diseases and the presence of neuropsychiatric and musculoskeletal diseases. Conclusion Among the older adult population studied, the prevalence of potentially anappropriate medication is high, according to the four different classification criteria used. As a more specific tool, the agreement between Anticholinergic Risk Scale and other criteria was lower, but it can be an important complement to other lists.
Similar content being viewed by others
References
Paradella R. Número de idosos cresce 18% em 5 anos e ultrapassa 30 milhões em 2017. In: Agência de Notícias. Fundação Instituto Brasileiro de Geografia e Estatística (IBGE). 2018. https://agenciadenoticias.ibge.gov.br/agencia-noticias/2012-agencia-de-noticias/noticias/20980-numero-de-idosos-cresce-18-em-5-anos-e-ultrapassa-30-milhoes-em-2017. Accessed: 26 Oct 2019.
Ministério da Saúde (BR). Política Nacional da Atenção Básica. Ministério da Saúde. 2012. https://189.28.128.100/dab/docs/publicacoes/geral/pnab.pdf. Accessed 26 Oct 2019.
Samuel MJ. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–46.
Hermes GB. Utilização de medicamentos potencialmente inapropriados por idosos brasileiros. In: Repositório Digital LUME. Universidade Federal do Rio Grande do SUL. 2017. https://lume.ufrgs.br/handle/10183/169698. Accessed 24 Oct 2019.
Gorzoni ML, Fabbri RMA. Applicability of anticholinergic risk scale in hospitalized elderly persons. Rev Bras Geriatr Gerontol. 2017;20(1):123–8.
Rodríguez-Blanco R, Álvarez-García M, Villalibre-Calderón C, Piña-Ferreras LD, Junquera-Alonso S, Alonso-Lorenzo JC. Evaluación de la actualización de los criterios STOPP-START en atención primaria. Semergen. 2019;45:180–6 (Spanish).
Martins GA, Ribeiro AQ, Priore SE, Franceschini SCC, Acurcio FA. Uso de medicamentos potencialmente inadequados entre idosos do Município de Viçosa, Minas Gerais, Brasil: um inquérito de base populacional. Cad Saude Publica. 2015;31:2401–12 (Portuguese).
Pardo-Cabello AJ, Manzano-Gamero V, Zamora-Pasadas M, Gutiérrez-Cabello F, Esteva-Fernández D, Luna-Del Castillo JD, et al. Potentially inappropriate prescribing according to STOPP-2 criteria among patients discharged from Internal Medicine: prevalence, involved drugs and economic cost. Arch Gerontol Geriatr. 2018;74:150–4.
Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ. 2018;363:k4524.
Kaufmann CP, Tremp R, Hersberger KE, Lampert ML. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70:1–11.
American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.
Oliveira MG, Amorim WW, Oliveira CRB, Coqueiro HL, Gusmão LC, Passos LC. Consenso brasileiro de medicamentos potencialmente inapropriados para idosos. Geriatr Gerontol Aging. 2016;10:168–81.
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.
Almeida TA, Reis EA, Pinto IVL, Ceccato MGB, Silveira MR, Lima MG, et al. Factors associated with the use of potentially inappropriate medications by older adults in primary health care: an analysis comparing AGS Beers, EU(7)-PIM List, and Brazilian Consensus PIM criteria. Res Soc Adm Pharm. 2019;15(4):370–7.
Oliveira MG, Amorim WW, de Jesus SR, Heine JM, Coqueiro HL, Passos LCS. A comparison of the beers and STOPP criteria for identifying the use of potentially inappropriate medications among elderly patients in primary care. J Eval Clin Pract. 2015;21:320–5.
Oliveira MG, Amorim WW, De Jesus SR, Rodrigues VA, Passos LC. Factors associated with potentially inappropriate medication use by the elderly in the Brazilian primary care setting. Int J Clin Pharm. 2012;34:626–32.
Ribas C, de Oliveira KR. Perfil dos medicamentos prescritos para idosos em uma Unidade Básica de Saúde do município de Ijuí-RS. Rev Bras Geriatr Gerontol. 2014;17:99–114 (Portuguese).
Abramson J. WINPEPI (PEPI-for-Windows). In: Brixton health home. 2016. https://www.brixtonhealth.com/. Accessed 20 Mar 2020.
The 2015 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2015 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–46.
Pastor-Cano J, Aranda-García A, Gascón-Cánovas JJ, Sánchez-Ruiz JF, Rausell-Rausell VJ, Tobaruela-Soto M. Prescripción potencialmente inadecuada en mayores de 65 años según los criterios de Beers originales y su versión adaptada. Atención Primaria. 2018;50:106–13.
Carvalho MFC, Romano-Lieber NS, Bergsten-Mendes G, Secoli SR, Ribeiro E, Lebrão ML, et al. Polypharmacy among the elderly in the city of São Paulo, Brazil-SABE. Rev Bras Epidemiol. 2012;15(4):817–27.
Ramos LR, Tavares NUL, Bertoldi AD, Farias MR, Oliveira MA, Luiza VL, et al. Polypharmacy and polymorbidity in older adults in Brazil: a public health challenge. Rev Saúde Pública. 2016;50(suppl 2):9s.
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–51.
Maher RL, Hanlon JT, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014. https://doi.org/10.1517/14740338.2013.827660.
Köberlein J, Gottschall M, Czarnecki K, Thomas A, Bergmann A, Voigt K. General practitioners’ views on polypharmacy and its consequences for patient health care. BMC Fam Pract. 2013;14:119.
Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35(4):303–19.
Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS ONE. 2016;11(4):e0151066. https://doi.org/10.1371/journal.pone.0151066.
Boyd CM, Darer J, Boult C, Fried LP, Boult F, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–24.
Jean-Baptiste B, Corinne D, Marie-Margueritte D, François P. Potentially inappropriate medications (PIMs) and anticholinergic levels in the elderly: a population based study in a French region. Arch Gerontol Geriatr. 2014;59:630–5.
Motter FR, Fritzen JS, Hilmer SN, Paniz ÉV, Paniz VMV. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;4(6):679–700.
Miquel MDC, Cuervo MS, Silveira ED, Machuca IS, González-Blazquez S, Errasquin BM, et al. Potentially inappropriate drug prescription in older subjects across health care settings. Eur Geriatr Med. 2010;1:9–14.
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.
Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9:434–41.
Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc. 2011;59:875–80.
Magin PJ, Morgan S, Tapley A, McCowan C, Parkinson L, Henderson KM, et al. Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines’ levels of anticholinergic activity and clinical indications. J Clin Pharm Ther. 2016;41:486–92.
Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults. Arch Intern Med. 2010;170(18):1648–54.
Lutz BH, Miranda VIA, Bertoldi AD. Potentially inappropriate medications among older adults in Pelotas, Southern Brazil. Rev Saude Publica. 2017;51:52.
Davies EA, O’Mahony MS. Adverse drug reactions in special populations: the elderly. Br J Clin Pharmacol. 2015;80:796–807.
Moreno G, Mangione CM, Kimbro L, Vaisberg E, American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geriatr Soc. 2013;61(11):2020–6.
Prefeitura Municipal de Saúde (BR). REMUME - Relação Municipal de Medicamentos Essenciais. In: Prefeitura Municipal de Porto Alegre. 2018. https://lproweb.procempa.com.br/pmpa/prefpoa/sms/usu_doc/remume_arquivo_110518.pdf. Accessed 26 Oct 2019.
Fried TR, Niehoff KM, Street RL, Charpentier PA, Rajeevan N, Miller PL, et al. Effect of the tool to reduce inappropriate medications on medication communication and deprescribing. J Am Geriatr Soc. 2017;65:2265–71.
Boghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas‐Fernandez C, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3(3):CD011969. https://doi.org/10.1002/14651858.CD011969.pub2.
Acknowledgements
We would like to thank the health professionals of the Unidade Básica de Saúde Santa Cecília, Porto Alegre/Brazil.
Funding
This study was not funded by any institution.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors have no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Santos Garcia, T., Simas da Rocha, B., De Jezus Castro, S.M. et al. Potentially inappropriate medications for older adults in a primary healthcare unit in southern Brazil. Int J Clin Pharm 42, 911–922 (2020). https://doi.org/10.1007/s11096-020-01048-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-020-01048-7